Melinta Therapeutics has struck a deal to merge with Cempra. The agreement brings together two of the biotechs developing anti-infective drugs. ​

New Haven-based Melinta will emerge from the merger as the dominant partner. Its name will stay above the door and its shareholders will control 52% of the combined company.​